RankingsPricing
  1. US-listed companies
  2. Ultragenyx Pharmaceutical Inc.
  3. Financials
  4. FCF margin (%)

Ultragenyx Pharmaceutical Inc.RARE

Market cap
$3.1B
P/E ratio
SummaryFinancials
Period EndFCF margin (%) YoY (%)
Dec 31, 2024-75.3-37.03%
Dec 31, 2023-119.5-12.54%
Dec 31, 2022-136.7+16.64%
Dec 31, 2021-117.2+80.33%
Dec 31, 2020-65-81.80%
Dec 31, 2019-357-37.61%
Dec 31, 2018-572.2-94.18%
Dec 31, 2017-9,825.3-92.37%
Dec 31, 2016-128,694

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating income Operating expenses Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSAdjusted EPSDividend payout ratio (%)Dividend per shareAdjusted DPSEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)